Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Small Cell Lung Cancer With HER2- Mutations × CP protocol × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Non-Small Cell Lung Cancer With HER2- Mutations 1 Non Small Cell Lung Carcinoma NSCLC 1 Lung Neoplasms 1

Interventions

Cisplatin 1 CP protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting

Non-Small Cell Lung Cancer With HER2- Mutations

Data powered by HemOnc (CC BY 4.0) Colophon ⚡